Elliott Levy

Elliott Levy, MD, joined LianBio as Clinical Advisor in January 2022. Dr. Levy has worked in the pharma industry since 1997, spending all but four years in the field of Clinical Development. Elliott most recently led the Clinical Development organization at Amgen as Senior Vice President, Global Development. In this role he oversaw over 70 programs, giving him one of the broadest clinical development roles in the industry, and gained approval for over two medicines per year on average, more than doubling the size of Amgen’s marketed product portfolio. Prior to joining Amgen in 2014, Elliott served as Senior Vice President and head of Specialty Development at Bristol Myers Squibb.

Over the course of Elliott’s career, he has played a major role in the development of over 20 approved medicines at two companies (BMS and Amgen) across 6 therapeutic areas – CV/Metabolic, Inflammation, Nephrology, Oncology, Neuroscience, and Bone – including the first modern immunotherapy for cancer (Yervoy), first oncolytic virus for cancer (Imlygic), and first effective bispecific therapy (Blincyto). In addition to delivering medicines to market, Elliot has managed significant process and organizational transformation efforts, including the launch of novel operating models (strategic CRO partnering model and cloud-based PV database), widespread adoption of innovative adaptive trial methodologies and data-driven approaches to study and program design, and utilization of real-world data in all stages of product development.

Elliott received his B.A. from Yale College magna cum laude and MD from Yale Medical School cum laude. He was Chief Resident of Internal Medicine at Yale, and received further training at Yale in Nephrology and Clinical Epidemiology. He also served in the Nephrology faculty at Boston’s Brigham and Women’s Hospital.